| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYOT |
| Uniprot No | Q9UBF9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-498aa |
| 氨基酸序列 | MFNYERPKHF IQSQNPCGSR LQPPGPETSS FSSQTKQSSI IIQPRQCTEQ RFSASSTLSS HITMSSSAFP ASPKQHAGSN PGQRVTTTYN QSPASFLSSI LPSQPDYNSS KIPSAMDSNY QQSSAGQPIN AKPSQTANAK PIPRTPDHEI QGSKEALIQD LERKLKCKDT LLHNGNQRLT YEEKMARRLL GPQNAAAVFQ AQDDSGAQDS QQHNSEHARL QVPTSQVRSR STSRGDVNDQ DAIQEKFYPP RFIQVPENMS IDEGRFCRMD FKVSGLPAPD VSWYLNGRTV QSDDLHKMIV SEKGLHSLIF EVVRASDAGA YACVAKNRAG EATFTVQLDV LAKEHKRAPM FIYKPQSKKV LEGDSVKLEC QISAIPPPKL FWKRNNEMVQ FNTDRISLYQ DNTGRVTLLI KDVNKKDAGW YTVSAVNEAG VTTCNTRLDV TARPNQTLPA PKQLRVRPTF SKYLALNGKG LNVKQAFNPE GEFQRLAAQS GLYESEEL |
| 预测分子量 | 55,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MYOT重组蛋白的3篇代表性文献(示例格式，非真实文献)：
1. **《Recombinant human myotilin expression and purification for antibody development》**
- **作者**: Smith A, et al.
- **摘要**: 研究通过大肠杆菌系统表达重组人MYOT蛋白，优化纯化流程并用于制备特异性抗体，验证其在肌肉组织中的免疫反应性。
2. **《Myotilin mutations alter the stability of recombinant protein and induce aberrant actin aggregation》**
- **作者**: Johnson R, et al.
- **摘要**: 分析MYOT致病突变体(如S55F)对重组蛋白结构和功能的影响，发现突变导致肌动蛋白异常聚集，提示其在肌营养不良症中的作用机制。
3. **《Structural characterization of the myotilin N-terminal domain using NMR spectroscopy》**
- **作者**: Lee H, et al.
- **摘要**: 通过核磁共振技术解析重组MYOT蛋白N端结构域的三维构象，揭示其与α-actinin结合的分子基础及对肌节组装的影响。
4. **《In vitro modeling of myotilinopathy using recombinant protein aggregates》**
- **作者**: García-Sánchez D, et al.
- **摘要**: 利用重组MYOT蛋白构建体外聚集模型，模拟病理蛋白沉积过程，评估其对肌细胞活力的影响及潜在治疗策略。
---
注：以上内容为模拟生成，实际文献需通过PubMed/Google Scholar检索关键词“myotilin recombinant”或结合具体研究方向筛选。
**Background of MYOT Recombinant Protein**
MYOT (myotilin) is a sarcomeric protein predominantly expressed in skeletal and cardiac muscles, playing a critical role in maintaining the structural integrity of Z-discs—the cross-linked networks that anchor actin filaments in muscle cells. Encoded by the *MYOT* gene, myotilin interacts with actin, α-actinin, and other Z-disc proteins to stabilize thin filaments and ensure proper muscle contraction. Mutations in *MYOT* are linked to several myopathies, including limb-girdle muscular dystrophy (LGMD), myofibrillar myopathy (MFM), and rare forms of cardiomyopathy, characterized by protein aggregation, sarcomere disorganization, and progressive muscle weakness.
Recombinant MYOT protein, produced via genetic engineering in systems like *E. coli* or mammalian cells, enables researchers to study its biochemical properties, interactions, and pathological mechanisms. Its production often involves tagging (e.g., His-tag) for purification and detection. Studies using recombinant MYOT have elucidated its role in actin bundling, stress fiber formation, and pathological aggregation, providing insights into disease pathways. For example, mutant MYOT proteins show reduced actin-binding capacity, leading to Z-disc instability and toxic protein clumps.
Additionally, recombinant MYOT serves as an antigen for antibody development, a tool for diagnostic assays, and a target for drug screening. Challenges remain in mimicking post-translational modifications (e.g., phosphorylation) critical for its function, necessitating advanced expression systems. Ongoing research aims to leverage MYOT recombinant protein to design therapies that restore sarcomere stability or dissolve aggregates, potentially mitigating MYOT-related myopathies.
In summary, MYOT recombinant protein is pivotal for unraveling muscle biology and pathology, bridging molecular insights to therapeutic innovation.
×
